NEULAND
WHERE OPPORTUNITY BECOMES REALITY

Neuland Laboratories Limited
Sanali Info Park, 'A' Block,
Ground Floor, 8-2-120/113
Road No. 2, Banjara Hills
Hyderabad - 500 034.
Telangana, India.

Tel: 040 30211600 / 23551081
Fax: 040 30211602
Email: neuland@neulandlabs.com
www.neulandlabs.com

December 13, 2017

To
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001
**Scrip Code: 524558**

To
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 001
**Scrip Code: NEULANDLAB**
**Series: EQ**

Dear Sirs,

**Sub: Press Release**

Further to our letter dated December 12, 2017, on Purchase of Manufacturing facility, please find enclosed a copy of the Press release being issued by the Company. The same is being uploaded on the website of the Company.

This is for your information and records.

Thanking you,

Yours faithfully,

For **Neuland Laboratories Limited**

**Sarada Bhamidipati**
**Company Secretary**

Encl : as above

# Neuland acquires ~197 KL Advanced Intermediates and API Facility near Hyderabad

**Hyderabad, India, December 13, 2017** – Neuland Laboratories Limited(NLL) (NSE: NEULANDLAB; BSE-Scrip Code:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solution to customers located in around 80 countries, has announced that it has completed the acquisition of the facility of Arch Pharma labs Limited located near Hyderabad, India.

The facility is spread across approx. 12 acres and has a capacity of about 197 KL. It was inspected by the USFDA in 2015. It is a multi-product facility and has five production blocks for advance intermediate and API manufacturing. It also has capabilities for on-site development, analytical method development, quality control laboratory and a pilot plant.

Sucheth Davaluri, Vice Chairman and CEO stated that, 'The organisation is very excited to have acquired these assets. These were much needed to provide flexibility to our operations in the near term and more importantly to meet our growth aspirations over next few years.'

## About Neuland Laboratories Limited

For over 33 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 75 APIs, and it has filed around 51 U.S. drug master files (USDMFs) and a total of around 650 Regulatory filings in the European Union (EU) and other geographies. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit www.NeulandLabs.com.

**If you have any questions or require further information, please feel free to contact**

*IR Department at Neuland*
*Tel: +91 40 3021 1600, Email: ir@neulandlabs.com*
*Jenna Palmieri, Neuland Laboratories Inc., USA*
*Email:jenna@neulandlabs.com*
*Diwakar Pingle, Investor Relations, Christensen*
*Tel: +91 22 4215 0210, Email: dpingle@christensenir.com*